ABBOTT LABORATORIES Research and Development Expense
ABBOTT LABORATORIES (ABT) reported Research and Development Expense of $767.00 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-04-29
- ABBOTT LABORATORIES research and development expense for the quarter ending 2026-03-31 was $767.00M, a 7.12% increase year-over-year.
- ABBOTT LABORATORIES research and development expense for the quarter ending 2025-12-31 was $735.00M, a 1.87% decline year-over-year.
- ABBOTT LABORATORIES research and development expense for the quarter ending 2025-09-30 was $766.00M, a 7.43% increase year-over-year.
- ABBOTT LABORATORIES research and development expense for the quarter ending 2025-06-30 was $725.00M, a 3.87% increase year-over-year.
- ABBOTT LABORATORIES research and development expense for fiscal 2025 was $2.94B, a 3.45% increase from fiscal 2024.
- ABBOTT LABORATORIES research and development expense for fiscal 2024 was $2.84B, a 3.76% increase from fiscal 2023.
- ABBOTT LABORATORIES research and development expense for fiscal 2023 was $2.74B, a 5.09% decline from fiscal 2022.
- ABBOTT LABORATORIES research and development expense for fiscal 2022 was $2.89B, a 5.32% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-03-31 | $767.00M 10-Q · filed 2026-04-29 | $1.50B derived: sum of 2 quarters · filed 2026-04-29 | $2.27B derived: sum of 3 quarters · filed 2026-04-29 | $2.99B derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-12-31 | $735.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $1.50B derived: sum of 2 quarters · filed 2026-02-20 | $2.23B derived: sum of 3 quarters · filed 2026-02-20 | $2.94B 10-K · filed 2026-02-20 |
| 2025-09-30 | $766.00M 10-Q · filed 2025-10-29 | $1.49B derived: sum of 2 quarters · filed 2025-10-29 | $2.21B 10-Q · filed 2025-10-29 | $2.96B derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-06-30 | $725.00M 10-Q · filed 2025-07-30 | $1.44B 10-Q · filed 2025-07-30 | $2.19B derived: sum of 3 quarters · filed 2026-04-29 | $2.90B derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-03-31 | $716.00M 10-Q · filed 2026-04-29 | $1.47B derived: sum of 2 quarters · filed 2026-04-29 | $2.18B derived: sum of 3 quarters · filed 2026-04-29 | $2.88B derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $749.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $1.46B derived: sum of 2 quarters · filed 2026-02-20 | $2.16B derived: sum of 3 quarters · filed 2026-02-20 | $2.84B 10-K · filed 2026-02-20 |
| 2024-09-30 | $713.00M 10-Q · filed 2025-10-29 | $1.41B derived: sum of 2 quarters · filed 2025-10-29 | $2.10B 10-Q · filed 2025-10-29 | $2.79B derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | $698.00M 10-Q · filed 2025-07-30 | $1.38B 10-Q · filed 2025-07-30 | $2.08B derived: sum of 3 quarters · filed 2026-02-20 | $2.75B derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | $684.00M 10-Q · filed 2025-04-30 | $1.38B derived: sum of 2 quarters · filed 2026-02-20 | $2.06B derived: sum of 3 quarters · filed 2026-02-20 | $2.77B derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | $700.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $1.37B derived: sum of 2 quarters · filed 2026-02-20 | $2.09B derived: sum of 3 quarters · filed 2026-02-20 | $2.74B 10-K · filed 2026-02-20 |
| 2023-09-30 | $672.00M 10-Q · filed 2024-10-31 | $1.39B derived: sum of 2 quarters · filed 2024-10-31 | $2.04B 10-Q · filed 2024-10-31 | $2.77B derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | $715.00M 10-Q · filed 2024-07-31 | $1.37B 10-Q · filed 2024-07-31 | $2.09B derived: sum of 3 quarters · filed 2025-02-21 | $2.88B derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | $654.00M 10-Q · filed 2024-05-02 | $1.38B derived: sum of 2 quarters · filed 2025-02-21 | $2.16B derived: sum of 3 quarters · filed 2025-02-21 | $2.85B derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | $725.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $1.51B derived: sum of 2 quarters · filed 2025-02-21 | $2.19B derived: sum of 3 quarters · filed 2025-02-21 | $2.89B 10-K · filed 2025-02-21 |
| 2022-09-30 | $782.00M 10-Q · filed 2023-11-01 | $1.47B derived: sum of 2 quarters · filed 2023-11-01 | $2.16B 10-Q · filed 2023-11-01 | $2.92B derived: sum of 4 quarters · filed 2024-02-16 |
| 2022-06-30 | $684.00M 10-Q · filed 2023-08-03 | $1.38B 10-Q · filed 2023-08-03 | $2.14B derived: sum of 3 quarters · filed 2024-02-16 | $2.81B derived: sum of 4 quarters · filed 2024-02-16 |
| 2022-03-31 | $697.00M 10-Q · filed 2023-05-04 | $1.46B derived: sum of 2 quarters · filed 2024-02-16 | $2.13B derived: sum of 3 quarters · filed 2024-02-16 | $2.79B derived: sum of 4 quarters · filed 2024-02-16 |
| 2021-12-31 | $762.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | $1.43B derived: sum of 2 quarters · filed 2024-02-16 | $2.09B derived: sum of 3 quarters · filed 2024-02-16 | $2.74B 10-K · filed 2024-02-16 |
| 2021-09-30 | $672.00M 10-Q · filed 2022-11-01 | $1.33B derived: sum of 2 quarters · filed 2022-11-01 | $1.98B 10-Q · filed 2022-11-01 | $2.68B derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-06-30 | $654.00M 10-Q · filed 2022-08-02 | $1.31B 10-Q · filed 2022-08-02 | $2.01B derived: sum of 3 quarters · filed 2023-02-17 | $2.59B derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-03-31 | $654.00M 10-Q · filed 2022-05-03 | $1.35B derived: sum of 2 quarters · filed 2023-02-17 | $1.93B derived: sum of 3 quarters · filed 2023-02-17 | $2.50B derived: sum of 4 quarters · filed 2023-02-17 |
| 2020-12-31 | $698.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $1.28B derived: sum of 2 quarters · filed 2023-02-17 | $1.84B derived: sum of 3 quarters · filed 2023-02-17 | $2.42B 10-K · filed 2023-02-17 |
| 2020-09-30 | $580.00M 10-Q · filed 2021-11-03 | $1.14B derived: sum of 2 quarters · filed 2021-11-03 | $1.72B 10-Q · filed 2021-11-03 | $2.32B derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-06-30 | $564.00M 10-Q · filed 2021-08-04 | $1.14B 10-Q · filed 2021-08-04 | $1.74B derived: sum of 3 quarters · filed 2022-02-18 | $2.33B derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-03-31 | $578.00M 10-Q · filed 2021-05-05 | $1.17B derived: sum of 2 quarters · filed 2022-02-18 | $1.77B derived: sum of 3 quarters · filed 2022-02-18 | $2.35B derived: sum of 4 quarters · filed 2022-02-18 |
| 2019-12-31 | $595.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $1.19B derived: sum of 2 quarters · filed 2022-02-18 | $1.77B derived: sum of 3 quarters · filed 2022-02-18 | $2.44B 10-K · filed 2022-02-18 |
| 2019-09-30 | $596.00M 10-Q · filed 2020-11-04 | $1.17B derived: sum of 2 quarters · filed 2020-11-04 | $1.84B 10-Q · filed 2020-11-04 | $2.41B derived: sum of 4 quarters · filed 2021-02-19 |
| 2019-06-30 | $577.00M 10-Q · filed 2020-07-29 | $1.25B 10-Q · filed 2020-07-29 | $1.81B derived: sum of 3 quarters · filed 2021-02-19 | $2.38B derived: sum of 4 quarters · filed 2021-02-19 |
| 2019-03-31 | $672.00M 10-Q · filed 2020-04-29 | $1.23B derived: sum of 2 quarters · filed 2021-02-19 | $1.81B derived: sum of 3 quarters · filed 2021-02-19 | $2.38B derived: sum of 4 quarters · filed 2021-02-19 |
| 2018-12-31 | $562.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $1.14B derived: sum of 2 quarters · filed 2021-02-19 | $1.71B derived: sum of 3 quarters · filed 2021-02-19 | $2.30B 10-K · filed 2021-02-19 |
| 2018-09-30 | $574.00M 10-Q · filed 2019-10-31 | $1.15B derived: sum of 2 quarters · filed 2019-10-31 | $1.74B 10-Q · filed 2019-10-31 | |
| 2018-06-30 | $575.00M 10-Q · filed 2019-07-31 | $1.16B 10-Q · filed 2019-07-31 | ||
| 2018-03-31 | $589.00M 10-Q · filed 2019-05-01 | |||
| 2017-12-31 | $2.26B 10-K · filed 2020-02-21 | |||
| 2012-03-31 | $50.00M 10-Q · filed 2012-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |